These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 15138582)
1. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes. Ko BK; Efferson CL; Kawano K; Kuerer HM; Sahin A; Murray JL; Ioannides CG Int J Oncol; 2004 Jun; 24(6):1413-8. PubMed ID: 15138582 [TBL] [Abstract][Full Text] [Related]
2. Helper peptide G89 (HER-2:777-789) and G89-activated cells regulate the survival of effectors induced by the CTL epitope E75 (HER-2, 369-377). Correlation with the IFN-gamma: IL-10 balance. Lee TV; Johnston DA; Thomakos N; Honda T; Efferson CL; Ioannides CG Anticancer Res; 2002; 22(3):1481-90. PubMed ID: 12168827 [TBL] [Abstract][Full Text] [Related]
3. HER-2 peptides p776 and F7, N-terminal-linked with Ii-Key tetramer (LRMK) help the proliferation of E75-TCR+ cells: The dependency of help on the side chains of LRMK-extended peptide pointed towards the T cell receptor. Li Y; Ishiyama S; Matsueda S; Tsuda N; Ioannides CG Oncol Rep; 2008 Jun; 19(6):1445-52. PubMed ID: 18497949 [TBL] [Abstract][Full Text] [Related]
4. Stimulation of human T cells by an influenza A vector expressing a CTL epitope from the HER-2/neu protooncogene results in higher numbers of antigen-specific TCRhi cells than stimulation with peptide. Divergent roles of IL-2 and IL-15. Efferson CL; Kawano K; Tsuda N; Palese P; García-Sastre A; Ioannides CG Anticancer Res; 2005; 25(2A):715-24. PubMed ID: 15868901 [TBL] [Abstract][Full Text] [Related]
5. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277 [TBL] [Abstract][Full Text] [Related]
6. Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death. Kawano K; Efferson CL; Peoples GE; Carter D; Tsuda N; Murray JL; Ioannides CG Cancer Res; 2005 Apr; 65(7):2930-7. PubMed ID: 15805296 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621 [TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer. Zehbe I; Kaufmann AM; Schmidt M; Hohn H; Maeurer MJ J Immunother; 2007; 30(5):523-32. PubMed ID: 17589293 [TBL] [Abstract][Full Text] [Related]
9. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Dubsky P; Saito H; Leogier M; Dantin C; Connolly JE; Banchereau J; Palucka AK Eur J Immunol; 2007 Jun; 37(6):1678-90. PubMed ID: 17492620 [TBL] [Abstract][Full Text] [Related]
10. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer. Goedegebuure PS; Douville CC; Doherty JM; Linehan DC; Lee KY; Ganguly EK; Eberlein TJ Cell Immunol; 1997 Feb; 175(2):150-6. PubMed ID: 9023420 [TBL] [Abstract][Full Text] [Related]
11. Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex. Castilleja A; Carter D; Efferson CL; Ward NE; Kawano K; Fisk B; Kudelka AP; Gershenson DM; Murray JL; O'Brian CA; Ioannides CG J Immunol; 2002 Oct; 169(7):3545-54. PubMed ID: 12244144 [TBL] [Abstract][Full Text] [Related]
12. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Murray JL; Gillogly ME; Przepiorka D; Brewer H; Ibrahim NK; Booser DJ; Hortobagyi GN; Kudelka AP; Grabstein KH; Cheever MA; Ioannides CG Clin Cancer Res; 2002 Nov; 8(11):3407-18. PubMed ID: 12429628 [TBL] [Abstract][Full Text] [Related]
13. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme. Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247 [TBL] [Abstract][Full Text] [Related]
14. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. Tuttle TM; Anderson BW; Thompson WE; Lee JE; Sahin A; Smith TL; Grabstein KH; Wharton JT; Ioannides CG; Murray JL Clin Cancer Res; 1998 Aug; 4(8):2015-24. PubMed ID: 9717833 [TBL] [Abstract][Full Text] [Related]
15. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines. Anichini A; Scarito A; Molla A; Parmiani G; Mortarini R J Immunol; 2003 Aug; 171(4):2134-41. PubMed ID: 12902520 [TBL] [Abstract][Full Text] [Related]
16. Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes. Rohrer JW; Barsoum AL; Dyess DL; Tucker JA; Coggin JH J Immunol; 1999 Jun; 162(11):6880-92. PubMed ID: 10352310 [TBL] [Abstract][Full Text] [Related]
17. Identification of activated tumor antigen-reactive CD8+ cells in healthy individuals. Lee TV; Anderson BW; Peoples GE; Castilleja A; Murray JL; Gershenson DM; Ioannides CG Oncol Rep; 2000; 7(3):455-66. PubMed ID: 10767352 [TBL] [Abstract][Full Text] [Related]
18. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940 [TBL] [Abstract][Full Text] [Related]
19. Distribution and functional analysis of memory antiviral CD8 T cell responses in HIV-1 and cytomegalovirus infections. Ellefsen K; Harari A; Champagne P; Bart PA; Sékaly RP; Pantaleo G Eur J Immunol; 2002 Dec; 32(12):3756-64. PubMed ID: 12516570 [TBL] [Abstract][Full Text] [Related]